Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective decreased by investment analysts at HC Wainwright from $12.00 to $5.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 21.65% from the company’s current price.

INO has been the subject of several other reports. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday. Oppenheimer decreased their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Inovio Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $38.00.

Inovio Pharmaceuticals Price Performance

INO traded down $0.16 on Monday, reaching $4.11. 281,042 shares of the company’s stock were exchanged, compared to its average volume of 402,191. The stock has a market cap of $106.70 million, a PE ratio of -1.14 and a beta of 0.83. Inovio Pharmaceuticals has a twelve month low of $4.10 and a twelve month high of $14.75. The stock’s fifty day moving average price is $5.75 and its 200-day moving average price is $8.14.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in INO. Bank of New York Mellon Corp purchased a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth $661,000. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals during the second quarter worth about $88,000. Rhumbline Advisers grew its position in Inovio Pharmaceuticals by 5,943.0% during the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 37,857 shares during the period. American Century Companies Inc. increased its holdings in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at approximately $184,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.